论文部分内容阅读
目的 :探讨恶性肿瘤DNA倍体分类在肿瘤患者预后方面的依据。方法 :用流式细胞术 (FCM)对 130例恶性肿瘤患者癌组织DNA含量进行检测 ,并分析了癌组织不同倍体类型与肿瘤患者生存率和生存期的关系。结果 :恶性肿瘤患者DNA倍体类型不同 ,患者生存率和生存期明显不同。DNA二倍体肿瘤患者的生存率和生存期显著高于异倍体患者 (P <0 .0 5)。在DNA异倍体患者中 ,从ND→T→AN→M ,患者生存率逐渐下降 ,生存期逐渐缩短 ,而且ND、T与AN、M肿瘤患者的生存率和生存期之间差异均有显著性 (P <0 .0 5)。结论 :肿瘤患者癌细胞DNA倍体不同 ,预后也明显不同。从D、ND→T→AN→M肿瘤 ,患者预后越来越差。该结果为癌组织DNA倍体分类提供了预后方面的依据
Objective : To explore the basis of DNA ploidy classification of malignant tumors in the prognosis of patients with cancer. Methods : Flow cytometry (FCM) was used to detect the DNA content in cancer tissues of 130 patients with malignant tumors. The relationship between the different ploidy types of cancer tissues and the survival rate and survival time of tumor patients was analyzed. Results: The patients with malignant tumors had different types of DNA ploidy, and the survival rate and survival time were significantly different. The survival and survival of patients with DNA diploid tumors were significantly higher than those of patients with aneuploidy (P < 0.05). In patients with DNA aneuploidy, the survival rate gradually decreased from ND→T→AN→M, the survival period gradually decreased, and there was a significant difference between the survival rate and survival time of ND, T and AN, M tumor patients. Sex (P < 0.05). Conclusion: Cancer patients have different DNA ploidy and different prognosis. From D, ND→T→AN→M tumors, the prognosis of patients is getting worse. This result provides a prognostic basis for DNA ploidy classification in cancer tissues.